<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
        xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url>
    <loc>https://losingweightrx.com/news/retatrutide-triumph-1-phase-3-weight-loss-results</loc>
    <news:news>
      <news:publication>
        <news:name>Losing Weight RX</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-05-29</news:publication_date>
      <news:title>Retatrutide Delivers 28% Weight Loss in TRIUMPH-1 Phase 3 Trial</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://losingweightrx.com/news/nih-study-explains-glp1-weight-loss-plateaus</loc>
    <news:news>
      <news:publication>
        <news:name>Losing Weight RX</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-05-29</news:publication_date>
      <news:title>NIH Study Explains Why GLP-1 Weight Loss Plateaus Happen</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://losingweightrx.com/news/medicare-wegovy-zepbound-coverage-july-2026</loc>
    <news:news>
      <news:publication>
        <news:name>Losing Weight RX</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-05-29</news:publication_date>
      <news:title>Medicare to Cover Wegovy and Zepbound at $50/Month Starting July 1</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://losingweightrx.com/news/glp1-drugs-cancer-metastasis-risk-asco-2026</loc>
    <news:news>
      <news:publication>
        <news:name>Losing Weight RX</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-05-29</news:publication_date>
      <news:title>GLP-1 Drugs Linked to Lower Cancer Metastasis Risk in ASCO Study</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://losingweightrx.com/news/semaglutide-exercise-muscle-preservation-study</loc>
    <news:news>
      <news:publication>
        <news:name>Losing Weight RX</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-05-29</news:publication_date>
      <news:title>Combining Semaglutide With Exercise Preserves Muscle, Boosts Fat Loss</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://losingweightrx.com/news/fda-peptide-guidelines-restrict-sermorelin-access</loc>
    <news:news>
      <news:publication>
        <news:name>Losing Weight RX</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-05-29</news:publication_date>
      <news:title>FDA Peptide Rules Restrict Sermorelin Access</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://losingweightrx.com/news/elysium-health-launches-waitlist-personalized-longevity-teli</loc>
    <news:news>
      <news:publication>
        <news:name>Losing Weight RX</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-05-29</news:publication_date>
      <news:title>Elysium Health Launches Longevity Program Waitlist</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://losingweightrx.com/news/nadrestore-trial-recommends-split-dosing-muscle-nad</loc>
    <news:news>
      <news:publication>
        <news:name>Losing Weight RX</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-05-29</news:publication_date>
      <news:title>NADRESTORE Trial Backs Split-Dosing for Muscle NAD+</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://losingweightrx.com/news/uconn-study-warns-against-combining-senolytic-longevity-drugs</loc>
    <news:news>
      <news:publication>
        <news:name>Losing Weight RX</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-05-29</news:publication_date>
      <news:title>UConn Warns Against Combining Senolytic Longevity Drugs</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://losingweightrx.com/news/cvs-caremark-cover-foundayo-restore-zepbound</loc>
    <news:news>
      <news:publication>
        <news:name>Losing Weight RX</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-05-29</news:publication_date>
      <news:title>CVS Caremark Expands Zepbound and Foundayo Coverage</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://losingweightrx.com/news/ai-uncovers-hidden-glp1-side-effects-reddit-study</loc>
    <news:news>
      <news:publication>
        <news:name>Losing Weight RX</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-05-30</news:publication_date>
      <news:title>AI Uncovers Hidden GLP-1 Side Effects From 400K Reddit Posts</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://losingweightrx.com/news/fda-proposes-permanent-ban-compounded-semaglutide-tirzepatide</loc>
    <news:news>
      <news:publication>
        <news:name>Losing Weight RX</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-05-30</news:publication_date>
      <news:title>FDA Proposes Permanent Ban on Compounded GLP-1 Drugs</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://losingweightrx.com/news/wegovy-eye-stroke-risk-higher-than-ozempic-bmj-study</loc>
    <news:news>
      <news:publication>
        <news:name>Losing Weight RX</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-05-30</news:publication_date>
      <news:title>Wegovy Linked to 5x Higher Eye Stroke Risk vs Ozempic</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://losingweightrx.com/news/glp1-brain-reward-circuit-emotional-blunting-study</loc>
    <news:news>
      <news:publication>
        <news:name>Losing Weight RX</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-05-30</news:publication_date>
      <news:title>GLP-1 Drugs and the Brain: Study Maps Reward Changes</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://losingweightrx.com/news/fda-advisory-panel-review-bpc157-tb500-peptides-july</loc>
    <news:news>
      <news:publication>
        <news:name>Losing Weight RX</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-05-30</news:publication_date>
      <news:title>FDA Advisory Panel to Review BPC-157, TB-500 and 5 Other Peptides in July</news:title>
    </news:news>
  </url>
</urlset>
